TimesSquare Capital Management LLC Purchases New Shares in Xenon Pharmaceuticals Inc. $XENE

TimesSquare Capital Management LLC acquired a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the 2nd quarter, Holdings Channel reports. The firm acquired 451,593 shares of the biopharmaceutical company’s stock, valued at approximately $27,258,000.

A number of other institutional investors and hedge funds have also made changes to their positions in XENE. Danske Bank A S bought a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter worth about $32,000. Kestra Advisory Services LLC bought a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $33,000. Osaic Holdings Inc. lifted its holdings in shares of Xenon Pharmaceuticals by 541.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,034 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Xenon Pharmaceuticals in the fourth quarter worth about $43,000. Finally, Rockefeller Capital Management L.P. grew its position in Xenon Pharmaceuticals by 450.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,100 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 900 shares in the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. boosted their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. HC Wainwright reiterated a “buy” rating and issued a $74.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, August 10th. Royal Bank Of Canada cut their target price on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. Finally, Needham & Company LLC decreased their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $77.13.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, Director Gary Patou sold 1,322 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the sale, the director directly owned 24,896 shares of the company’s stock, valued at approximately $1,322,973.44. The trade was a 5.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the transaction, the director directly owned 1,455 shares in the company, valued at $77,318.70. This represents a 44.99% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 12,512 shares of company stock valued at $774,088 in the last quarter. 2.91% of the stock is owned by insiders.

Xenon Pharmaceuticals Trading Up 0.0%

Shares of NASDAQ:XENE opened at $62.36 on Tuesday. Xenon Pharmaceuticals Inc. has a 12 month low of $35.60 and a 12 month high of $72.66. The company has a market capitalization of $6.03 billion, a price-to-earnings ratio of -13.16 and a beta of 0.62. The firm’s 50-day moving average is $61.57 and its 200 day moving average is $55.22.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.05. During the same period in the previous year, the business posted ($1.07) EPS. As a group, equities analysts forecast that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current fiscal year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.